Vulvovaginitis Treatment Guidelines

Introduction to Vulvovaginitis

The American College of Obstetricians and Gynecologists recommends topical azole agents or oral fluconazole 150mg as a single dose as equally effective first-line options for uncomplicated vulvovaginitis cases, with high-quality evidence 1

Uncomplicated vulvovaginitis typically responds well to standard therapy, accounting for approximately 90% of cases, according to the Centers for Disease Control and Prevention 1
Complicated vulvovaginitis requires longer treatment durations and specialized approaches based on the causative organism, as recommended by the Infectious Diseases Society of America 1
Women with uncontrolled diabetes or on corticosteroid treatment require more prolonged therapy (7-14 days), according to the MMWR Recommendations and Reports 2

Vaginal pH measurement can help diagnose the cause of vaginal odor, with a pH >4.5 suggesting bacterial vaginosis (BV) or trichomoniasis, and a pH ≤4.5 suggesting candidiasis or normal flora, as recommended by the CDC 2, 3
Microscopy using saline wet mount and 10% KOH preparation improves visualization of yeast and pseudohyphae, as recommended by the CDC 2
Diagnostic characteristics of vaginal infections include:
The following table summarizes the key features of bacterial vaginosis and vulvovaginal candidiasis:

Feature	Bacterial Vaginosis	Vulvovaginal Candidiasis
Discharge	Homogeneous, white, thin	White, thick, "cottage cheese-like"
Odor	Fishy or musty	Usually minimal or none
pH	>4.5	≤4.5 (normal)
Key symptom	Discharge and odor	Intense itching
First-line treatment	Metronidazole 500mg BID x 7 days	Topical azoles or fluconazole 150mg single dose	[3]

Oral fluconazole 150mg as a single dose is a recommended first-line option for uncomplicated vulvovaginitis, with high-quality evidence, according to the Clinical Infectious Diseases guidelines 1
Extended topical therapy with azole agents for 7-14 days is also a recommended first-line option, as stated by the MMWR Recommendations and Reports 2
Treatment options for bacterial vaginosis (BV) include:
Treatment options for vulvovaginal candidiasis (VVC) include:

For unresponsive cases, boric acid 600mg in a gelatin capsule, administered vaginally once daily for 14 days, is a recommended alternative option, according to the Clinical Infectious Diseases guidelines 1
Nystatin intravaginal suppositories, 100,000 units daily for 14 days, and topical 17% flucytosine cream alone or with 3% amphotericin B cream daily for 14 days, are also alternative options, as recommended by the Clinical Infectious Diseases guidelines 1

Fluconazole 150mg weekly for 6 months is a recommended maintenance therapy regimen, according to the Clinical Infectious Diseases guidelines 1
Alternative maintenance regimens include clotrimazole 500mg vaginal suppositories once weekly, ketoconazole 100mg once daily, and itraconazole 400mg once monthly or 100mg once daily, as stated by the MMWR Recommendations and Reports 2

Women with HIV should receive the same treatment regimens as those without HIV for VVC, BV, and trichomoniasis, according to the American Academy of Family Physicians 4
Only topical azole therapies should be used during pregnancy, with 7-day treatment courses recommended 5
Treatment options for BV in pregnant women include:
The use of probiotics as an adjunctive therapy alongside standard antibiotic treatment for bacterial vaginosis significantly improves cure rates and reduces recurrence compared to antibiotics alone, with a risk ratio of 1.53 (95% CI 1.19-1.97) for probiotics in BV treatment 6
Probiotic supplementation has a higher risk ratio of 1.60 (95% CI 1.16-2.22) when restricted to high-quality studies, indicating improved efficacy in bacterial vaginosis treatment 6

Untreated bacterial vaginosis is associated with complications such as preterm labor, premature rupture of membranes, spontaneous abortion, and increased risk of sexually transmitted infections, as stated by the American Family Physician 7
Treatment of sex partners is essential to prevent reinfection, according to the American Academy of Family Physicians, although routine notification or treatment of sexual partners is not warranted for VVC or BV 4, 5, 2
Patients should avoid sexual intercourse until treatment is complete and symptoms resolve, particularly with trichomoniasis, as recommended by the American Academy of Family Physicians 4

Patients should return for follow-up only if symptoms persist or recur 5
Women experiencing three or more episodes per year should be evaluated for predisposing conditions 5
Daily lukewarm baths (30 minutes) can help remove discharge and debris, and mild antiseptic baths two to three times a week can be considered if recurrent infection is a concern, using chlorhexidine, octenidine, or polyhexanide, as recommended by the British Journal of Dermatology and supported by the Royal College of Obstetricians and Gynaecologists 8
No long-term maintenance regimen is currently available for BV 5
Recurrence of BV is common; alternative treatment regimens can be used for recurrent disease 5

Topical agents may cause local burning or irritation 5
Oral fluconazole may cause nausea, abdominal pain, and headaches 5
Metronidazole may cause disulfiram-like reactions if consumed with alcohol, and patients should be advised to avoid consuming alcohol during treatment and for 24 hours thereafter 2
Clindamycin cream and ovules are oil-based and might weaken latex condoms and diaphragms, which should be considered when prescribing these treatments 2